The Door Opens Wider For Drug Companies To Make Off-Label Claims

The FDA has finally reached a settlement in its long dispute with Amarin Corporation, manufacturer of the prescription fish oil product Vascepa. Last year a US judge ruled against the FDA.  The settlement brings an end to the litigation and will permit Amarin to promote off-label usage of Vascepa as long as its statements are...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized Amarin Caronia FDA first amendment Fish oil REDUCE-IT Vascepa Source Type: blogs